Skip to main content
BCIFlex (智冉医疗) logo

BCIFlex (智冉医疗)

Beijing, ChinaSee on the mapFounded 2022

  • Brain-computer interfaces
  • Series B

BCIFlex is a Chinese medical device company developing a next-generation invasive brain-computer interface platform based on ultra-thin flexible electrodes. Founded in 2022, it combines expertise in advanced materials, micro- and nano-manufacturing, artificial intelligence, and neuroscience to create technologies for neural signal acquisition, decoding, and clinical applications.

Raised
$175M
Sep 2026
Series B
Investors
21
Founded
2022

reccy insights

Recent highlights

BCIFlex’s most recent disclosed financing milestone was a Series B announced on Sep 21, 2026, raising $89.6 million. That followed two Series A rounds: $41.8 million on Aug 4, 2025, with Legend Capital君联资本 and IDG Capital named as lead investors, and $43.4 million on Feb 11, 2026, led by 西安中科创星科技孵化器有限公司. The six listed rounds total $174.8 million, with three earlier rounds—two Seed rounds and an Angel round—having no disclosed amounts here. The company describes its work as developing invasive brain-computer interfaces using ultra-thin flexible electrodes, with capabilities spanning neural signal acquisition, signal decoding, and electrode implantation. Its stated clinical application areas include functional replacement and restoration, functional recovery, and neuromodulation. The company also reports more than 40 domestic and international patents, five R&D laboratories, and about 2,000 square meters of production space.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes BCIFlex (智冉医疗) distinct

  1. 01Focuses on invasive brain-computer interfaces built around ultra-thin flexible electrodes.
  2. 02Combines work in advanced materials, micro- and nano-manufacturing, artificial intelligence, and neuroscience.
  3. 03Develops technologies for neural signal acquisition, brain-signal decoding, and electrode implantation.
  4. 04Reports more than 40 domestic and international patents, five R&D laboratories, and approximately 2,000 square meters of production space.
  5. 05Targets clinical applications including functional replacement and restoration, functional recovery, and neuromodulation.

Technology & products8

  • Wireless implantable signal acquisition system

    A system for acquiring neural signals through an implantable, wireless platform.

  • Ultra-thin flexible electrodes

    Flexible electrodes designed for invasive brain-computer interface applications.

  • Implantable signal acquisition device

    An implantable device for neural signal acquisition.

Research roots2

Labs and research groups this company came from or works with.

Academic data: Carter Sciences

Recent updates1

  • Mar 30, 2026Product launch

    智冉医疗千通道侵入式脑机接口系统重磅首发!央视、新华社等权威媒体争相报道

    mp.weixin.qq.com

Funding

$175M disclosed
  • Series BSep 2026
    $89.6M
  • Series AFeb 2026
    $43.4MLed by 西安中科创星科技孵化器有限公司
  • Series AAug 2025
21 investors

Investors13

Also backed by
  • 西安中科创星科技孵化器有限公司
  • Beijing Pharma & Health Industry Investment Fund
  • BV Baidu Ventures
  • CAS Star (中科创星)
  • Jiayin Capital
  • Lenovo Capital
  • Meituan DragonBall
  • Shunwei Capital
  • Xingze Capital
  • Yuansheng Capital

Similar companies

About BCIFlex (智冉医疗)

Products
Wireless implantable signal acquisition system, Ultra-thin flexible electrodes, Implantable signal acquisition device, Brain-signal decoding algorithms, Electrode implantation robot, Thousand-channel invasive brain-computer interface system, Digital electroencephalograph, SEEG intracranial depth electrodes
Focus areas
Neurotechnology, medical devices, digital health, artificial intelligence, flexible electronics, implantable devices, brain-computer interfaces
Headquarters
Beijing, China
Founded
2022